Clinical trials: Oral Stage
Colitis, Ulcerative
Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.
- Trial name
- NCT06176560
- Testing
- Mesalazine
- Volunteers
- 376 people
- Sponsor
- Faes Farma, S.A.
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Breast Cancer, Colorectal Cancer
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.
- Conditions
- Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma
- Trial name
- NCT03422679
- Testing
- CB-103
- Where
- 17 sites in United States, France and 4 more
- Volunteers
- 79 people
- Sponsor
- Cellestia Biotech AG
Obesity
A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese
The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: how the study medicine, danuglipron, is taken up into the…
- Trial name
- NCT06567327
- Testing
- Danuglipron, Atorvastatin, Rosuvastatin
- Where
- 3 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Pfizer
Allergies
Evaluation of the Efficacy of Oral Immunotherapy With Raw Apple in Patients Allergic to Birch Pollen and Apple: Prospective, Multicenter, Comparative Phase III Study
Apple-birch pollen-food allergy syndrome is particularly common in Northern and Central Europe (70% of patients allergic to birch pollen), and classically induces an oral syndrome that impairs patients' quality of life.
- Trial name
- ELIO (NCT06771791)
- Testing
- oral provocation test
- Where
- 4 sites in France
- Volunteers
- 110 people
- Sponsor
- University Hospital, Strasbourg, France
Healthy Subjects
First-into-human Study of NS-136 in Healthy Subjects
The goal of this clinical trial is to exlplore the profile of NS-136 in health conditions. The main questions it aims to answer are: Is NS-136 safe and tolerable in heathy subjects under tested dosing regimen? What is the…
- Trial name
- NCT06345703
- Testing
- NS-136 tablet
- Where
- 2 sites in Australia, China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- NeuShen Therapeutics
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
NADPH oxidase enzymes (NOX) have been implicated in the development of several diabetic complications including diabetic nephropathy. GKT137831 is the first in class NOX1/4 inhibitor.
- Trial name
- NCT02010242
- Testing
- GKT137831
- Where
- 48 sites in United States, Australia and 4 more
- Volunteers
- 136 people
- Sponsor
- Calliditas Therapeutics AB
Acne
Efficacy of Cosmetic Product RV3278B-OS0386 in the Maintenance Phase After Oral Isotretinoin Treatment of Adults Subjects With Facial Acne.
The aim of this study is to evaluate the efficacy of the RV3278B-OS0386 cosmetic product, compared to the control product in managing acne relapse during the 12-month maintenance phase follow-up after oral isotretinoin treatment…
- Trial name
- NCT07341659
- Testing
- Test product RV3278BB-OS0386, Control product RV3278B-OS0548
- Where
- 5 sites in France, Italy and 1 more
- Volunteers
- 102 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Periodontitis (Stage 3), Periodontitis Stage III
Three-Session Non-Surgical Periodontal Therapy Improves Biochemical and Microbiological Profiles in Patients With Severe Grade C Periodontitis
This clinical study investigates two different non-surgical periodontal therapy approaches in patients with advanced periodontitis and compares them with periodontally healthy individuals.
- Trial name
- TSTG (NCT07272980)
- Testing
- Scaling and Root Planing (SRP)
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Gülnur Emingil
Secondary Hyperparathyroidism
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
This is an open-label, dose-ranging study of the vitamin D analog DP001 in patients with end-stage renal disease (ESRD). The primary goals of this 4-week Phase 2A study are to identify an appropriate starting dose of DP001 to be…
- Trial name
- NCT01653379
- Testing
- DP001
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Deltanoid Pharmaceuticals
Candidiasis
Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis
The purpose of this study is to further evaluate the safety and effectiveness of intravenous anidulafungin (Eraxis™) in patients with a diagnosis of candidemia or invasive candidiasis, which is a fungus infection of the blood or…
- Trial name
- NCT00496197
- Testing
- Eraxis (anidulafungin), Diflucan (fluconazole), Vfend (voriconazole)
- Where
- 43 sites in United States, South Korea
- Volunteers
- 282 people
- Sponsor
- Pfizer
Meconium Ileus, Very Low Birth Weight Infant
Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants
Gastrografin is a radiopaque contrast agent for the gastrointestinal tract (GIT) which can be applied orally or rectally. In neonatal intensive care, Gastrografin is used to detect otherwise radiologically invisible perforations…
- Trial name
- NCT01515696
- Testing
- Gastrografin, Sterile water
- Volunteers
- 96 people
- Sponsor
- Nadja Haiden,MD
Carcinoma, Non-small-cell Lung
A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer
The primary aim is to evaluate the safety (Phase I components) of administering bexarotene (Targretin®, LGD1069) oral capsules in combination with two Taxol® and carboplatin (Paraplatin®) schedules to patients with stage IIIB and…
- Trial name
- NCT00153842
- Testing
- Bexarotene (targretin)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Cancer, Xerostomia
Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors
The 3 Specific Aims are (1) To determine the prevalence, incidence and severity of oral conditions in postmenopausal early stage breast cancer survivors within the first 18 months of adjuvant Aromatase Inhibitor(AI) therapy, (2)…
- Trial name
- NCT01272570
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Metastatic Colorectal Cancer
TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC
Primary Objective: To determine disease control rate (DCR) of TS-1® in patients with heavily pre-treated metastatic colorectal cancer Secondary Objectives: To determine objective response rate (ORR) To determine time to…
- Trial name
- NCT03517618
- Testing
- S-1+leucovorin
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- TTY Biopharm
Healthy Volunteer
A Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Participants
This is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending, Single- and Multiple-Oral Dose, Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Subjects.
- Trial name
- NCT02471859
- Testing
- GDC-3280
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Myelodysplastic Syndromes, Anemia
Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948
Anemia in LR-MDS patients
- Trial name
- LUCAS (NCT05178342)
- Testing
- CA-4948
- Where
- 15 sites in Germany
- Volunteers
- 38 people
- Sponsor
- University of Leipzig
NSCLC
Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer
This is a multicenter, open-label, randomised, phase III study of 2 cycles of oral vinorelbine in combination with cisplatin concurrently with radiotherapy randomised to either two more cycles of consolidation therapy with oral…
- Trial name
- NCT00683514
- Testing
- Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)
- Where
- Germany
- Volunteers
- 201 people
- Sponsor
- Pierre Fabre Medicament
Acute Myeloid Leukemia With FLT3/ITD Mutation
A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants
This study plans to enroll 45 (Groups A, B, and C) to 75 healthy participants (including the sample size of other potential dose groups). The participants will be divided into three dose groups: 37.5 mg, 75 mg, and 150 mg.
- Trial name
- XY0206-CQT (NCT07162116)
- Testing
- XY0206, Moxifloxacin (400 mg)
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
Invasive Aspergillosis
Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects
A Phase I, open label study evaluating safety, tolerability and pharmacokinetics of F901318 in healthy subjects following up to 28 days dosing, where F901318 is given orally .
- Trial name
- NCT03340597
- Testing
- F901318
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- F2G Ltd